Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602657 | 0.81 | CA1 (0.36) | ALDH1A1NR1H4CA1CA2 | |
| SCHEMBL15423452 | 0.78 | ALDH1A1 (0.36) | ALDH1A1NPSR1CA12CA1CA2 | |
| SCHEMBL15423458 | 0.78 | ALDH1A1 (0.40) | ALDH1A1NPSR1 | |
| SCHEMBL6864014 | 0.76 | DHFR (0.31) | NPSR1 | |
| SCHEMBL13729390 | 0.76 | FFAR3 (0.35) | NPSR1 | |
| SCHEMBL19447702 | 0.75 | ALDH1A1 (0.34) | ALDH1A1NPSR1 | |
| SCHEMBL16841641 | 0.75 | ALDH1A1 (0.34) | ALDH1A1NPSR1 | |
| SCHEMBL24687410 | 0.71 | ALDH1A1 (0.32) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL15593749 | 0.71 | NR1H4 (0.36) | ALDH1A1NPSR1NR1H4CA12CA1 | |
| SCHEMBL15491264 | 0.71 | NPSR1 (0.33) | ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206884-A | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | 吉利德科学公司 | 2022-03-18 | — | — | CN | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-8987195-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8828930-B2 | Hepatitis C virus NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140057836-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-02-27 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | ALDH1A1 1179/4885NPSR1 4173/4885NR1H4 622/4885 |
| US-20140057836-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, TMPRSS15, CTSC | ALDH1A1 1222/4885NPSR1 3713/4885NR1H4 368/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 125/4885NPSR1 3473/4885NR1H4 18/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885NPSR1 3244/4885NR1H4 15/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885NPSR1 3244/4885NR1H4 15/4885 |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | ALDH1A1 883/4885NPSR1 3898/4885NR1H4 174/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | ALDH1A1 200/4885NPSR1 3899/4885NR1H4 16/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885NPSR1 3244/4885NR1H4 15/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885NPSR1 3244/4885NR1H4 15/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | ALDH1A1 200/4885NPSR1 3899/4885NR1H4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.